The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ORGANIZATION
ORGANIZATION
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
- Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
June 8, 2020
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
- JGA Chief Sawai to Stay in His Post, Deputy Chief Tamura Stepping Down
June 4, 2020
- JPMA Reprimands Torii, Nippon Chemiphar over Price-Fixing
May 29, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
May 29, 2020
- Generic/Biosimilar Society Calls on MHLW to Ensure Stable API Supply
May 26, 2020
- Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
May 22, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
May 21, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
- Japan Pharmacist Group Opposes Off-Year Re-Pricing in FY2021
May 1, 2020
- PhRMA, EFPIA Issue Joint Statement on Air Transporting Critical Medicines amid COVID-19 Outbreak
April 30, 2020
- JMA Calls for Early Avigan Use in High-Risk Patients Hospitalized with COVID-19
April 30, 2020
- IFPW Postpones Tokyo General Meeting to October 2021
April 27, 2020
- SMA Patient Group Presses MHLW to Hasten Zolgensma Listing
April 17, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…